OAM
ALXN

Oppenheimer Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Oppenheimer Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,561
Closed -$1.49M – 1223
2020
Q4 		$1.49M Buy
9,561
+421
+5% +$54.1K 0.02% 561
2020
Q3 		$1.05M Buy
9,140
+743
+9% +$80.2K 0.02% 603
2020
Q2 		$942K Buy
8,397
+931
+12% +$98.8K 0.02% 612
2020
Q1 		$670K Buy
7,466
+1,051
+16% +$103K 0.02% 661
2019
Q4 		$694K Buy
6,415
+797
+14% +$85.2K 0.01% 721
2019
Q3 		$550K Sell
5,618
-2,149
-28% -$242K 0.01% 783
2019
Q2 		$1.02M Sell
7,767
-520
-6% -$67K 0.02% 616
2019
Q1 		$1.12M Sell
8,287
-15,023
-64% -$1.87M 0.03% 582
2018
Q4 		$2.27M Sell
23,310
-1,850
-7% -$219K 0.06% 341
2018
Q3 		$3.5M Buy
25,160
+1,220
+5% +$153K 0.08% 294
2018
Q2 		$2.97M Buy
23,940
+705
+3% +$82.4K 0.07% 308
2018
Q1 		$2.59M Buy
23,235
+1,035
+5% +$124K 0.07% 322
2017
Q4 		$3.11M Hold
22,200
– – 0.08% 283
2017
Q3 		$3.11M Buy
22,200
+965
+5% +$131K 0.08% 285
2017
Q2 		$2.58M Sell
21,235
-1,326
-6% -$154K 0.07% 300
2017
Q1 		$2.73M Buy
+22,561
New +$2.91M 0.08% 284

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer Asset Management's ALXN Position: Q1 2021 in Review

Oppenheimer Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 9,561 shares — an estimated $1.49M sold.

Oppenheimer Asset Management first reported a position in ALXN in Q1 2017 and held it in 16 quarters. The position peaked at $3.5M in Q3 2018. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Oppenheimer Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Oppenheimer Asset Management sold 9,561 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.49M.
  • Oppenheimer Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 16 quarters.
  • Oppenheimer Asset Management's Alexion Pharmaceuticals position peaked at $3.5M in Q3 2018.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Oppenheimer Asset Management's 13F filing for Q1 2021, filed 17 May 2021.